# Insulin-like growth factor-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0503 - Language: en - Last updated: not specified - Page title: Insulin-like growth factor-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts | WCP 2026 Summary > IGF-1 levels decrease progressively across illness stages, increase with weight restoration and treatment, and are independently associated with the recovery o… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0503) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0503 E-PosterEating DisordersCross-sectional population-based analysis and 12-month clinical cohort # Insulin-like growth factor-1 and recovery in anorexia nervosa: evidence from population-based and clinical cohorts IGF-1 AND RECOVERY IN ANOREXIA NERVOSA: EVIDENCE FROM POPULATION-BASED AND CLINICAL COHORTS Presenter: Cristiano Dani Country: Italy Institution: Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence IGF-1 levels decrease progressively across illness stages, increase with weight restoration and treatment, and are independently associated with the recovery of menstrual function. The aim was to examine growth hormone (GH) resistance and low insulin-like growth factor-1 (IGF-1) levels across illness stages in anorexia nervosa (AN), and their associations with metabolic and reproductive parameters. A cross-sectional, population-based analysis was conducted within the UK Biobank, comparing 129 individuals with current AN (C-AN), 2,380 individuals with weight-restored AN (WR-AN), and 2,380 healthy controls (HC) matched for age and body mass index (BMI). An independent clinical cohort of 189 adult women was also assessed at baseline and at 12 months; group differences were examined using adjusted ANCOVA, and longitudinal changes using mixed-effects models. IGF-1 levels were 19.80±5.07 in the C-AN group, 21.70±5.69 in the WR-AN group, and 22.21±5.77 nmol/L in the HC group, with a significant difference between groups (F=11.10, p<0.001; post-hoc Tukey a